A multicentre prospective cohort study performed in France found that changes in the S100A12 expression levels in patients with RA were a good predictor of the clinical therapeutic efficacy of TNFis in RA and created a multivariate model to accurately predict RA patient responses to TNFis that can be used in everyday practice for individualized treatment [34]. The gene discussed is S100A12; the disease is rheumatoid arthritis.